StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy, 'High Ambitions, High Reward'
February 8, 2018 8:49 AM
Roth Capital initiates coverage on Conatus Pharmaceuticals (NASDAQ: CNAT) with a Buy rating and a price target of $20.00.Analyst Yasmeen ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot New Coverage
New Coverage